Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development

被引:12
作者
Shashidharamurthy, Rangaiah [1 ]
Bozeman, Erica N. [1 ]
Patel, Jaina [1 ]
Kaur, Ramneet [1 ]
Meganathan, Jeyandra [1 ]
Selvaraj, Periasamy [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
cancer vaccine; cancer immunotherapy; protein transfer; glycosylphosphatidylinositol (GPI); cytokines; immunostimulatory molecules; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; ANTIBODY-CALICHEAMICIN CONJUGATE; ANTI-CD20; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; GLYCOLIPID-ANCHORED IL-12; TUMOR-SPECIFIC IMMUNITY; ACUTE MYELOID-LEUKEMIA; PHASE-II TRIAL; GENE-TRANSFER;
D O I
10.1002/med.20237
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cancer cells have developed numerous ways to escape immune surveillance and gain unlimited proliferative capacity. Currently, several chemotherapeutic agents and radiotherapy, either alone or in combination, are being used to treat malignancies. However, both of these therapies are associated with several limitations and detrimental side effects. Therefore, recent scientific investigations suggest that immunotherapy is among the most promising new approaches in modern cancer therapy. The focus of cancer immunotherapy is to boost both acquired and innate immunity against malignancies by specifically targeting tumor cells, and leaving healthy cells and tissues unharmed. Cellular, cytokine, gene, and monoclonal antibody therapies have progressively become promising immunotherapeutic approaches that are being tested for several cancers in preclinical models as well as in the clinic. In this review, we discuss recent advances in these immunotherapeutic approaches, focusing on new strategies that allow the expression of specific immunostimulatory molecules on the surface of tumor cells to induce robust antitumor immunity.
引用
收藏
页码:1197 / 1219
页数:23
相关论文
共 170 条
  • [11] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [12] Immunotherapy of cancer
    Borghaei, Hossein
    Smith, Mitchell R.
    Campbell, Kerry S.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) : 41 - 54
  • [13] Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
    Borrello, Ivan M.
    Levitsky, Hyam I.
    Stock, Wendy
    Sher, Dorie
    Qin, Lu
    DeAngelo, Daniel J.
    Alyea, Edwin P.
    Stone, Richard M.
    Damon, Lloyd E.
    Linker, Charles A.
    Maslyar, Daniel J.
    Hege, Kristen M.
    [J]. BLOOD, 2009, 114 (09) : 1736 - 1745
  • [14] Cancer vaccine development: Designing tumor cells for greater immunogenicity
    Bozeman, Erica N.
    Shashidharamurthy, Rangaiah
    Paulos, Simon A.
    Palaniappan, Ravi
    D'Souza, Martin
    Selvaraj, Periasamy
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2010, 15 : 309 - 320
  • [15] Therapeutic antibodies for human diseases at the dawn of the twenty-first century
    Brekke, OH
    Sandlie, I
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (01) : 52 - 62
  • [16] L-arginine metabolism in myeloid cells controls T-lymphocyte functions
    Bronte, V
    Serafini, P
    Mazzoni, A
    Segal, DM
    Zanovello, P
    [J]. TRENDS IN IMMUNOLOGY, 2003, 24 (06) : 302 - 306
  • [17] BRUNSCHWIG EB, 1995, J IMMUNOL, V155, P5498
  • [18] Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery
    Bumgarner, Gary W.
    Shashidharamurthy, Rangaiah
    Nagarajan, Shanmugam
    D'Souza, Martin J.
    Selvaraj, Periasamy
    [J]. JOURNAL OF CONTROLLED RELEASE, 2009, 137 (02) : 90 - 97
  • [19] Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial
    Burch, PA
    Croghan, GA
    Gastineau, DA
    Jones, LA
    Kaur, JS
    Kylstra, JW
    Richardson, RL
    Valone, FH
    Vuk-Pavlovic, S
    [J]. PROSTATE, 2004, 60 (03) : 197 - 204
  • [20] Burton ER, 2009, J BIOL, V8, P851